1. Home
  2. NXPL vs COCH Comparison

NXPL vs COCH Comparison

Compare NXPL & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextPlat Corp

NXPL

NextPlat Corp

SELL

Current Price

$7.20

Market Cap

25.8M

ML Signal

SELL

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

N/A

Current Price

$6.85

Market Cap

51.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NXPL
COCH
Founded
1997
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Blank Checks
Sector
Telecommunications
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
51.3M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
NXPL
COCH
Price
$7.20
$6.85
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $19.67
AVG Volume (30 Days)
19.7K
★ 31.8K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 35.29
17.45
EPS
★ N/A
N/A
Revenue
★ $5,869,558.00
$241,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$46.77
$15.33
P/E Ratio
★ N/A
N/A
Revenue Growth
2.50
★ 7.11
52 Week Low
$0.34
$4.72
52 Week High
$9.94
$47.70

Technical Indicators

Market Signals
Indicator
NXPL
COCH
Relative Strength Index (RSI) 37.29 18.42
Support Level $5.54 $4.72
Resistance Level $7.24 $7.46
Average True Range (ATR) 0.83 0.46
MACD -0.12 1.03
Stochastic Oscillator 38.88 43.44

Price Performance

Historical Comparison
NXPL
COCH

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: